RBC Capital downgraded Fisher & Paykel Healthcare to Underperform from Sector Perform with a price target of NZ$29, down from NZ$30. The downgrade follows the company’s FY25 results, which exceeded both RBC and consensus expectations, but showed a “significant slowdown” in revenue growth of hospital new application consumables and homecare consumables. The firm cited the stock’s “expensive valuation relative to its earnings outlook” for the downgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF:
- Fisher & Paykel Healthcare Surpasses $2 Billion Revenue Milestone
- Fisher & Paykel Healthcare Announces Dividend Distribution
- Fisher & Paykel Healthcare Achieves Record Revenue in 2025
- Fisher & Paykel Healthcare Announces Investor Event in Melbourne
- Pinnacle Investment Reduces Stake in Fisher & Paykel Healthcare